New research indicates that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds much more quickly than those who end traditional lifestyle programs.
Research printed in a prominent health publication points out that while overweight people often shed about a fifth of their body weight while using the jabs, the mass is regained at an average rate of nearly a kilo each month once they quit.
"People buying such drugs must be aware of the risk of fast weight regain when the treatment ends," warns researcher Dr. Susan Jebb.
Such speed of regain suggests a return to original mass within about 18 months.
Comparing Therapies
The research, which examined dozens of trials involving thousands of participants, contrasted the effects of these new drugs with other pills.
Scientists note that individuals who shed pounds through lifestyle changes alone generally have a slower creep back—around 0.1 kg a month—after stopping.
The Reason for the Quick Regain
Experts suggest the mode of action of the injections explains the heightened regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the system to produce less of its own natural hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means hunger is uncontrolled, making excessive eating much more probable."
A Chronic Condition?
Health authorities advise the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts say that, due to the likelihood of relapse, the treatment is often life-long.
This opinion is supported by drug manufacturers, who state that the findings "highlight the chronic character of excess weight," akin to managing conditions like diabetes.
Patient Experiences
Users who have come off the medication report a powerful return of appetite.
"It was like a trigger activating and you're instantly ravenous," described one woman.
The struggle is worsened if patients have not adopted lasting dietary or behavioural modifications during treatment.
Widespread Use
Recent estimates show that a significant number of people in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is more common among women than men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while these medications are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss relies on ongoing lifestyle support.
